How Can Abnormal Blood Vessel Growth In The Retina Be Stopped? – Arohi Eye Hospital

1. With clinical research being carried out in every field, the Harvard Medical School clinical team has identified a potential new therapy RUNX1 to considerably reduce abnormal blood vessel growth in the retina, which is a significant symptom of the diabetic eye disease. However, the research has been conducted only with in vitro laboratory studies of human retinal cells and mouse retinas. But, the researchers are hopeful that inhibiting RUNX1 may also help to manage abnormal retinal blood vessel growth in lots of eye conditions like diabetic eye disease, macular degeneration, and retinopathy. In fact, they are positive that patients can be given eye drops or systemic medications even before the abnormal blood vessels form in the eye, to prevent their development at all. To have your eyes checked for any such eye issues, especially if you are a patient of diabetes, you can walk in at Arohi Eye Hospital to have a professional and genuine eye consultation in Andheri West Mumbai, to help detect the exact problem that your eyes are suffering from. Current treatments to control retinal abnormal blood vessel growth require injecting very large proteins into the eyes of the patients once a month. But, this new study has opened the doors for novel modes of treatment based on small molecules that can cross biological barriers on their own. Such treatments can eliminate the need for injections. In the study, researchers studied tissues from patients with proliferative diabetic retinopathy. They identified the presence of RUNX1 in the diseased blood vessels, but not in normal blood vessels. They then used a small molecule drug, which was originally developed to treat cancer, to inhibit the activity of RUNX1 in the eye, which led to significant reduction of abnormal blood vessels. Titled as “Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis”, the new diabetes research had been published first online by the American Diabetes Association. All the normal and abnormal physical processes that occur with diabetes mellitus, including laboratory, animal, and

2. human research are presented on the “Diabetes” website where this research has been published. The authors involved with this publication include a long list –  Jonathan D. Lam, Daniel J. Oh, Lindsay L. Wong, Dhanesh Amarnani, Cindy Park Windhol, Angie V. Sanchez, Jonathan Cardona Velez, Declan McGuone, Anat O. Stemmer Rachamimov, Dean Eliott, Diane R. Bielenberg, Tave van Zyl, Lishuang Shen, Xiaowu Gai, Patricia A. D’Amore, Leo A. Kim, and Joseph F. Arboleda Velasquez, from Harvard Medical School, Boston Massachusetts General Hospital, Boston Children’s Hospital Los Angeles, Los Angeles Universidad Pontificia Bolivariana, Medellin, Colombia    Now, let us take a look at the various terminologies that are used in this research, to bring to you a better view of the entire study. 1.RUNX1 as a Mediator of Aberrant Retinal Angiogenesis – Identification of a protein that can change or reduce the abnormal blood vessel growth that occurs in retinal disease, including diabetic retinopathy 2.Angiogenesis – Growth of new blood vessels, which plays a crucial role in the normal development of body organs and tissue 3.In vitro – Processes taking place in a test tube or culture dish, typically in a laboratory RUNX1 – Runt-related transcription factor 1, a protein that is encoded by the RUNX1 gene. The RUNX1 protein activates genes that help in controlling the development of blood cells. Stay Connected With Us On: Facebook, Twitter, LinkedIn, Google+, Instagram